Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy

被引:31
|
作者
Chow, Vincent [1 ,2 ,3 ]
Reddel, Caroline [1 ,2 ,3 ]
Pennings, Gabrielle [1 ,2 ,3 ]
Scott, Elizabeth [4 ]
Pasqualon, Tundra [5 ]
Ng, Austin C. C. [2 ,3 ]
Yeoh, Thomas [2 ]
Curnow, Jennifer [1 ,3 ,6 ]
Kritharides, Leonard [1 ,2 ,3 ]
机构
[1] ANZAC Res Inst, Sydney, NSW, Australia
[2] Concord Repatriat Gen Hosp, Dept Cardiol, Sydney Local Hlth Dist, Concord, NSW 2139, Australia
[3] Univ Sydney, Sydney, NSW 2006, Australia
[4] Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2006, Australia
[5] Croydon Hlth Ctr, Dept Psychiat, Sydney, NSW, Australia
[6] Concord Repatriat Gen Hosp, Dept Haematol, Sydney Local Hlth Dist, Concord, NSW 2139, Australia
基金
英国医学研究理事会;
关键词
Schizophrenia; Blood coagulation test; Coagulation; Thrombosis; Fibrinolysis; HIGH-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; RISK-FACTOR; PULMONARY-EMBOLISM; PLASMA-LEVELS; PROTEIN-S; UNMEDICATED PATIENTS; LABORATORY METHOD;
D O I
10.1016/j.schres.2014.12.042
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Patients with schizophrenia are at increased risk of venous thromboembolism. The mechanisms underlying this association are poorly understood. Aims: We investigated whether there is a global hypercoagulable state in patientswith schizophrenia utilising the overall haemostatic potential (OHP) assay which assesses overall coagulation potential (OCP), haemostatic potential (OHP) and fibrinolytic potential (OFP). Method: Citrated plasma was collected for OHP assays from patients with schizophrenia on long-term antipsychotic treatment and compared with healthy age-and sex-matched controls. Time courses of fibrin formation and degradation were measured by spectrophotometry (absorption of 405 nm) after the addition of tissue factor and tissue plasminogen activator to plasma. Results: Ninety patients with schizophrenia (antipsychotic treatment-15.9 +/- 9.7 years) and 30 controls were recruited. Patients with schizophrenia had higher rates of smoking and levels of inflammatory markers (high-sensitivity C-reactive protein and neutrophil-to-lymphocyte ratio) than controls. Whilst D-dimer, fibrinogen and platelet count did not differ between patients with schizophrenia and controls, the OCP (54.0 +/- 12.6 vs 45.9 +/- 9.1, p = 0.002) and OHP (12.6 +/- 5.8 vs 7.2 +/- 3.7, p < 0.001) were higher, and OFP was lower (76.6 +/- 9.8% vs 84.9 +/- 6.4%, p < 0.001) in patients with schizophrenia, implying both a hypercoagulable and hypofibrinolytic state in these patients. Importantly, abnormalities in overall coagulation were independently predicted by levels of plasminogen-activator-inhibitor-1, fibrinogen, platelet count, inflammatory markers and plasma triglycerides, suggesting a multifactorial aetiology. Conclusion: Patients with schizophrenia have evidence of a global hypercoagulable and hypofibrinolytic state which may contribute to their increased risk of venous thromboembolism. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [21] INFLUENZA IMMUNIZATION IN PATIENTS RECEIVING LONG-TERM RIFAMPIN THERAPY
    ALBERT, R
    LAKSHMINARAYAN, S
    MILLER, W
    [J]. CHEST, 1977, 72 (03) : 392 - 392
  • [22] BONE DENSITY IN PATIENTS RECEIVING LONG-TERM ANTICONVULSANT THERAPY
    LINDE, J
    SIERSBAE.K
    HANSEN, JM
    FUGLSANG.V
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1971, 47 (05): : 650 - &
  • [23] Citrate kinetics in patients receiving long-term hemodialysis therapy
    Bauer, E
    Derfler, K
    Joukhadar, C
    Druml, W
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (05) : 903 - 907
  • [24] Sustainable Therapy of Schizophrenia - Utilizing modern Depot-Antipsychotic Drugs for long-term Therapy Success
    Vehling, Thomas
    [J]. NERVENHEILKUNDE, 2012, 31 (12) : 962 - 962
  • [25] The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
    Goff, Donald C.
    Falkai, Peter
    Fleischhacker, W. Wolfgang
    Girgis, Ragy R.
    Kahn, Rene M.
    Uchida, Hiroyuki
    Zhao, Jingping
    Lieberman, Jeffrey A.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (09): : 840 - 849
  • [26] Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
    Rubio, Jose M.
    Taipale, Heidi
    Tanskanen, Antti
    Correll, Christoph U.
    Kane, John M.
    Tiihonen, Jari
    [J]. SCHIZOPHRENIA BULLETIN, 2021, 47 (06) : 1611 - 1620
  • [27] Long-term health in schizophrenia: metabolic effects of antipsychotic treatments
    Haupt, D
    Van Gaal, L
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S662 - S662
  • [28] Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism
    Chow, Vincent
    Reddel, Caroline
    Pennings, Gabrielle
    Chung, Tommy
    Ng, Austin C. C.
    Curnow, Jennifer
    Kritharides, Leonard
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (05) : 537 - 544
  • [29] RISK FACTORS FOR NONCOMPLIANCE WITH ANTIPSYCHOTIC MEDICATION IN LONG-TERM TREATED CHRONIC SCHIZOPHRENIA PATIENTS
    Krzystanek, Marek
    Krysta, Krzysztof
    Janas-Kozik, Malgorzata
    Martyniak, Ewa
    Rybakowski, Janusz
    [J]. PSYCHIATRIA DANUBINA, 2019, 31 : S543 - S548
  • [30] Long-term antipsychotic treatment and corpus callosum volume: an MRI study in patients with schizophrenia
    Trehout, M.
    Leroux, E.
    Delcroix, N.
    Dollfus, S.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S924 - S925